CSL Ltd. plunged the most on record after the Australian biotechnology company cut its full-year outlook and flagged about $5 ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the ...

CSL now expects weaker full-year revenue and profit as plasma, China pricing, and Vifor pressures weigh on performance.

CSL said it now expects revenue of around $15.2 billion and an underlying net profit of $3.1 billion in the 12 months through June when currency swings are stripped out. The net profit measure, known ...

The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...

- Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring's portfolio KING OF ...

Moscow opening reinforces CSL Behring's promise to deliver its world-class therapies to patients with rare and serious diseases around the world. KING OF PRUSSIA, Pa. — 08 December 2015 - Global ...

CSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market subcutaneous (SC) injection 200mg Andembry pens designed to prevent acute ...

SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into ...

SYDNEY--Pharmaceutical company CSL on Monday downgraded its annual earnings guidance and signaled another $5 billion of pretax impairments, including for the Vifor business that it acquired for $11.7 ...